DME market across 7MM set to reach $11.1 billion in 2031, forecasts GlobalData

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved

OliX Pharmaceuticals submits application to U.S. FDA to evaluate safety and tolerability of OLX10212

The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.

50% of the world's population expected to be myopic by 2050

Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear

Grand Opening of Kodiak Sciences’ bioconjugation facility

Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases

Shilpa Medicare receives NoC for biosimilar Aflibercept

Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab

ENTOD Pharma bullish on Macushield sales

Macushield tablets assist with age-related macular degeneration, diabetic retinopathy and improves overall vision

Intas and Axantia sign an exclusive agreement for Ranibizumab biosimilar

Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US

Complement Therapeutics raises €5 million seed financing

Appoints Dr Rafiq Hasan as CEO

Kato wins USFDA approval for studies in retinal disorder

Resolv ER may remedy leading causes of blindness in adults